Your session is about to expire
← Back to Search
Hormonal Therapy for Early-Stage Breast Cancer
Study Summary
This trial is testing if hormonal therapy & monitoring can manage early-stage breast cancer effectively. Participants get treatment & MRI exams, plus provide samples to study immune & genetic factors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this particular clinical experiment recruiting participants at the present moment?
"Affirmative. Clinicaltrials.gov confirms that the trial, which was first made available on November 30th 2023, is presently seeking participants. 400 subjects need to be enrolled from 1 medical facility."
To what extent has participant recruitment been successful in this medical study?
"Affirmative. According to information on clinicaltrials.gov, recruitment for this experiment is ongoing and began November 30th 2023. The last revision was made 11/22/2023; 400 participants are needed from one site."
What adverse effects could result from patients taking Testosterone + Anastrazole (T+Ai)?
"The safety of Testosterone + Anastrazole (T+Ai) has been given a score of 2, as this Phase 2 trial only involves limited data on the medication's safety but none related to its efficacy."
Share this study with friends
Copy Link
Messenger